Merus N.V. Advances in Head and Neck Cancer Treatment with Phase 3 Study

Merus NV ((MRUS)) announced an update on their ongoing clinical study.

Merus N.V. is conducting a Phase 3 clinical study titled ‘A Phase 3 Open-label, Randomized Controlled Study to Evaluate the Efficacy and Safety of Petosemtamab Compared With Investigator’s Choice Monotherapy Treatment in Previously Treated Patients With Incurable, Metastatic/Recurrent Head and Neck Squamous Cell Carcinoma.’ The study aims to assess the efficacy and safety of Petosemtamab against standard monotherapy options in patients with progressive head and neck squamous cell carcinoma (HNSCC) who have already undergone anti-PD-1 and platinum-based therapies. This research is significant as it targets a critical need for effective treatments in advanced-stage HNSCC.

The intervention being tested is Petosemtamab, a drug designed to treat patients with incurable, metastatic, or recurrent HNSCC. It is compared against the investigator’s choice of standard treatments, including Cetuximab, Methotrexate, and Docetaxel.

The study follows an interventional design with randomized allocation and a parallel intervention model. It is open-label, meaning no masking is involved, and its primary purpose is treatment-focused.

The study began on June 25, 2024, with primary completion and estimated completion dates yet to be announced. The latest update was made on July 14, 2025, indicating ongoing recruitment and progress.

This update could positively influence Merus N.V.’s stock performance by showcasing its commitment to advancing cancer treatment options. Investors may view this as a promising development, especially in the competitive oncology market, where effective new therapies are highly valued.

The study is ongoing, and further details can be accessed on the ClinicalTrials portal.